OVID Heads Into Q3 Print With Shorts Retreating Fast

OVID enters its November 13 earnings print on the back of a sharp short squeeze in the lending market, with options traders positioned more bullishly than at almost any point in the past year.

The clearest shift in positioning is the rapid unwind of short interest. OVID's SI % of free float stands at 23.2%, still high in absolute terms, but the number has fallen roughly 33% over the past month, dropping from more than 26 million shares shorted in late September to around 16.5 million today. That is a substantial cover in a short time, and it coincides directly with the stock's 19% weekly gain. Borrow conditions are loose and getting looser: availability has expanded to 227%, well above the 52-week tightest level of 43%, meaning supply of shares to lend has grown substantially relative to what is already borrowed. Cost to borrow remains negligible at 0.70%, despite a 16% weekly rise, confirming that the retreat in short positions is driven by conviction rather than a forced squeeze. Options traders are equally bullish: the put/call ratio of 0.07 sits close to the 52-week low of 0.02, well below the 20-day mean of 0.12, reflecting heavy call bias into the print.

The bull-bear debate hinges entirely on whether OV329 can deliver a genuinely differentiated safety profile in epilepsy. The bull case, backed by a cluster of recent initiations, is that the drug avoids vigabatrin's retinal toxicity at dramatically lower doses, an unmet need worth over $700 million in peak worldwide revenue across tuberous sclerosis and infantile spasms. Wolfe Research, Cantor Fitzgerald and Guggenheim all initiated coverage with positive ratings in October, adding weight to the analyst consensus that sits well above the current price: the mean target of $6.40 implies more than 120% upside against the $2.85 close, with the analyst recommendation percentile ranking in the 93rd percentile. Bears counter that clinical risk is severe, all three indications carry a 20% combined probability of success in bear-case modelling, that KCC2 asset OV4071 is effectively valued at zero, and that the company is a cash-dependent pre-revenue story until at least 2029. The $169.8 million cash runway is not in dispute; what divides the market is whether the pipeline justifies anything above its cash value.

Institutional ownership tells a pointed story about who has been building conviction. BlackRock added approximately 9.3 million shares to reach 5.5% of shares outstanding (last reported September 30). State Street added 7.4 million shares in the same period. Vanguard added nearly 3 million. These are index-weight-agnostic additions from large active mandates, not passive rebalancing, and they arrived alongside the October analyst initiation wave. Janus Henderson holds 10.6% and Takeda Pharmaceutical remains on the register at 3.6%, a strategic overhang that carries different read-through from pure financial holders. Point72, by contrast, trimmed from 5.1% to 1.3% as of its May filing, a notable exit from a former 5%-plus holder.

The print will test whether the pipeline data-flow into upcoming PPR, TSC and OV4071 readouts is tracking to the schedule that drove October's wave of bullish analyst coverage, and whether the accelerating short cover reflects genuine reassessment of clinical risk or simply price momentum getting ahead of that evidence.